Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Liabilities: 2021-2024

Historic Total Liabilities for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $142.1 million.

  • Kiniksa Pharmaceuticals International's Total Liabilities rose 49.59% to $176.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.9 million, marking a year-over-year increase of 49.59%. This contributed to the annual value of $142.1 million for FY2024, which is 62.45% up from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's Total Liabilities is $142.1 million, which was up 62.45% from $87.5 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year Total Liabilities high stood at $142.1 million for FY2024, and its period low was $47.8 million during FY2021.
  • Its 3-year average for Total Liabilities is $97.7 million, with a median of $87.5 million in 2023.
  • Data for Kiniksa Pharmaceuticals International's Total Liabilities shows a peak YoY surged of 62.45% (in 2024) over the last 5 years.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's Total Liabilities stood at $47.8 million in 2021, then surged by 33.00% to $63.5 million in 2022, then skyrocketed by 37.72% to $87.5 million in 2023, then spiked by 62.45% to $142.1 million in 2024.